LA JOLLA, Calif., April 22, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient?s innate immune system to fight disease, announced today that the United States Patent and Trademark Office (USPTO) has given formal notice of allowance in patent application serial no. 15/268,399, titled ?IN VIVO PRIMING OF NATURAL KILLER CELLS,? which covers a method of treating cancer by administering a proprietary inactivated cellular material preparation and contacting a patient?s own natural killer cells within the body to induce an in vivo response, namely, the priming of NK cells for enhancing innate immunity and the NK cell ability to recognize and kill cancer cells within the patient.
News
INmune Bio to Present at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, September 10th at 2:10 p.m. ET
LA JOLLA, Calif., Sept. 05, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient?s innate immune system to fight disease, is pleased to announce that R.J. Tesi, M.D…. […]
News
INmune Bio Announces Publication of Data on INKmune Primed NK cells in Peer-Reviewed Journal PLOS ONE
LA JOLLA, Calif., June 27, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company developing treatments that harness the patient?s innate immune system to fight disease, announced today that the peer-reviewed open access s… […]
News
Correction: INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option
LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) — In a release issued under the same headline on Monday, July 20th by INmune Bio, Inc. (NASDAQ: INMB) was incorrectly reported with below sentence: […]
